Practice Management News

Fungal pathogens that can cause various diseases will likely become more prevalent in the next 10 years thanks to climate change, according to a recent commentary.

A surge of respiratory syncytial virus, an early start to influenza season and the ongoing COVID-19 pandemic have caused a “tripledemic” in the United States, overwhelming hospitals, experts said.

NEW YORK — In this video filmed at the Infectious Diseases in Children Symposium, John V. Williams, MD, describes multiple interventions in development against respiratory syncytial virus, which is currently surging in the United States.

NEW YORK — In this video, Healio Pediatrics Peer Perspective Board Member C. Buddy Creech, MD, MPH, summarizes the “COVID corner” session at the Infectious Diseases in Children Symposium, including his own talk on outpatient treatment.

NEW YORK — It is hoped that the future of COVID-19 vaccines for children will include simplifying the process of getting shots into their arms, CDC medical officer Sara E. Oliver, MD, MSPH, says in this video.

The bivalent COVID-19 booster vaccine from Pfizer-BioNTech elicited a stronger response against the BQ.1.1 sublineage than the companies’ original vaccine in people aged 55 years and older, according to new data from the companies.

There is still not enough evidence to make a recommendation for or against obstructive sleep apnea screening in asymptomatic adults, according to a statement from the U.S. Preventive Services Task Force.

Although clinical and cycle threshold value assessment can distinguish COVID-19 reinfection from detecting virus from a prior infection, it failed to identify 33% of genomically supported reinfections, according to a recent study.

Treasury Inflation Protected Securities, aka TIPS, provide investors with a return that is indexed to inflation over the life of the bond. With the sharp increase in inflation that began in 2021, many investors who own TIPS expected to see gains as a result.

PHILADELPHIA — Rituximab is comparable in terms of safety and efficacy to cyclophosphamide among patients with interstitial lung disease associated with connective tissue diseases, according to data presented at ACR Convergence 2022.